ConductScience.org, home

Paper40972782

Impact of empagliflozin and dapagliflozin on sudden cardiac death: A systematic review and meta-analysis of adjudicated randomized evidence.

Matteucci A and 10 others. Heart Rhythm, 2026. Cited by 40 papers, by iCite.

Cite this record

ConductScience Library. Impact of empagliflozin and dapagliflozin on sudden cardiac death: A systematic review and meta-analysis of adjudicated randomized evidence. Papers, record 40972782. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40972782

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Impact of empagliflozin and dapagliflozin on sudden cardiac death: A systematic review and meta-analysis of adjudicated randomized evidence.
PubMed
Journal
Heart Rhythm
PubMed
Year
2026
PubMed
Publication types
Journal Article, Systematic Review, Meta-Analysis
PubMed
Citations, by iCite
40
iCite
Relative citation ratio, by iCite
10.87, provisional
iCite
Revised in PubMed
2026-09-08
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Matteucci AAndrea
2Pandozi CClaudio
3Bonanni MMichela
4Mariani MVMarco Valerio
5Sgarra LLuca
6Nesti LLorenzo
7Pierucci NNicola
8La Fazia VMVincenzo Mirco
9Lavalle CCarlo
10Nardi FFederico
11Colivicchi FFurio

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
GlucosidesMajor topic
Benzhydryl CompoundsMajor topic
Death, Sudden, CardiacMajor topic
Sodium-Glucose Transporter 2 InhibitorsMajor topic
Diabetes Mellitus, Type 2Major topic
Humans
Randomized Controlled Trials as Topic

Source PubMed

Download CSV of topics

Cited by38

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 40 citations.

PMIDTitleJournalYearIn PapersSource
42963793Empagliflozin's role in cardiometabolic disease treatment: an Egyptian expert's view.Diabetol Metab Syndr2026https://conductscience.org/library/papers/42963793PubMed
42941631Drug Therapies and Incident Heart Failure in Atrial Fibrillation: A Systematic Review.J Clin Med2026https://conductscience.org/library/papers/42941631PubMed
42694338Safety & efficacy of sodium glucose co-transport 2 (SGLT2) inhibitors in elderly patients with heart failure.Front Cardiovasc Med2026https://conductscience.org/library/papers/42694338PubMed
42636098
Association of triglyceride-glucose (TyG)-Derived inflammatory indices with the risk of all-cause and cardiovascular mortality in patients with chronic kidney disease: A retrospective cohort study based on NHANES 1999-2018.
Sci Prog2026https://conductscience.org/library/papers/42636098PubMed
42491272Dapagliflozin Augmentation of Sacubitril/Valsartan Therapy in Patients With Heart Failure Following PCI-Treated Acute Myocardial Infarction: A Meta-Analysis of Clinical Efficacy and Safety.Cardiol Res Pract2026https://conductscience.org/library/papers/42491272PubMed
42466343Insulin resistance as a predictor of long-term adverse cardiovascular event risk in patients with atrial fibrillation following radiofrequency catheter ablation.Front Endocrinol (Lausanne)2026https://conductscience.org/library/papers/42466343PubMed
42426633Association of naples prognostic score and systemic immune-inflammation index with left ventricular recovery in peripartum cardiomyopathy.BMC Cardiovasc Disord2026https://conductscience.org/library/papers/42426633PubMed
42279224Prognostic Value of HALP and AHEAD Scores for Predicting 1-Month Heart Failure Following Myocardial Infarction.J Clin Med2026https://conductscience.org/library/papers/42279224PubMed
42122989Early Predictors of In-Hospital Mortality and Cardiac Dysfunction in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Early Revascularization.J Clin Med2026https://conductscience.org/library/papers/42122989PubMed
42074843Predicting Sudden Cardiac Death in Heart Failure with Mildly Reduced/Preserved Left Ventricular Ejection Fraction: A Clinical Review.J Clin Med2026https://conductscience.org/library/papers/42074843PubMed
41976977Prognostic Impact of Renin-Angiotensin System Inhibitors in Revascularized Patients with Acute Myocardial Infarction and Preserved or Mildly Reduced Ejection Fraction: A Retrospective Cohort Study.J Clin Med2026https://conductscience.org/library/papers/41976977PubMed
41899299Clinical and Comorbidity-Related Factors Associated with Health-Related Quality of Life in Patients with Heart Failure: A Cross-Sectional Study.J Clin Med2026https://conductscience.org/library/papers/41899299PubMed
41768590SGLT-2 inhibitors improve cardiac function in hypertrophic cardiomyopathy: a real-world propensity score-matched study.Front Cardiovasc Med2026https://conductscience.org/library/papers/41768590PubMed
41753361Cardio-Reno-Microvascular Phenotypes and Multifactorial Cardiometabolic Target Achievement in Type 2 Diabetes.J Clin Med2026https://conductscience.org/library/papers/41753361PubMed
41752660Heart Failure and Atrial Fibrillation in Women: Pathophysiological Links, Clinical Challenges, and Therapeutic Perspectives.Medicina (Kaunas)2026https://conductscience.org/library/papers/41752660PubMed
41752656Cardio-Vasculo-Renal Benefits of SGLT2 Inhibitors in Heart Failure: A Retrospective Study from a Lower-Resource Tertiary Center.Medicina (Kaunas)2026https://conductscience.org/library/papers/41752656PubMed
41745353Genetic Variants in Potassium Channel Genes and Their Clinical Implications in Kazakhstani Patients with Cardiac Arrhythmias.J Pers Med2026https://conductscience.org/library/papers/41745353PubMed
41727549Differential cardiovascular benefits of SGLT2 inhibitors, sacubitril/valsartan, omecamtiv mecarbil, and vericiguat across heart failure phenotypes: a systematic review and meta-analysis.Front Pharmacol2026https://conductscience.org/library/papers/41727549PubMed
41682737Patterns in Prescribing and Predictors of SGLT2 Inhibitor Administration in Patients with Heart Failure and Acute Myocardial Infarction: A Real-World Retrospective Cohort Study.J Clin Med2026https://conductscience.org/library/papers/41682737PubMed
41597491Early SGLT2 Inhibitor Therapy in Acute Coronary Syndrome: Mitigating Adverse Remodeling in High-Risk Phenotypes-A Real-World Study.Medicina (Kaunas)2026https://conductscience.org/library/papers/41597491PubMed

See all 38 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
SLC5A26524PubTator's text mininghttps://conductscience.org/library/genes/6524

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40972782

GET https://conductscience.org/api/papers/v1/40972782/cited_by?page=2